Fed Circ grants Teva temporary pause in Orange Book feud

Teva insisted panel’s narrow interpretation of ‘claims the drug’ will have a seismic effect on the Orange Book | Stay granted while en banc rehearing is under question | Decision could reshape patent listing standards and impact the availability of generic drugs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Hikma warns SCOTUS of ‘imminent threat’ for generic competition under ‘skinny label’ rules

Gilead deal staves off generic HIV drugs for another six years

Apple voids Omni MedSci wearable tech patent

Clifford Chance expands life sciences team with A&O Shearman hire

Vidal: ‘Erroneous’ jury instructions need to be fixed at Fed Circ

'A very good decision’: Patent industry welcomes UPC in-house reps update

Make a difference: Cast your vote in IP Diversity & Inclusion Awards 2025

Courtroom report: Regeneron’s $6bn biosimilar battle against Mylan

Fed Circ grants Teva temporary pause in Orange Book feud

Editor's picks

Editor's picks

More features